MedTrace Logo

Topical Cyclosporine-A for Management of Epiphora

NCT04637633 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2020-11-23

No results posted yet for this study

Summary

to investigate the clinical outcomes and tolerances of Cyclosporine A (CsA) in treating epiphora in eyes with acquired punctum stenosis

Conditions

  • Epiphora

Interventions

DRUG

topical 0.05% CsA (Restasis®, Allergan Inc, Irvine, California)twice daily dose,

topical preservative free artificial tears Q.I. D.

Sponsors & Collaborators

  • Farwaniya Hospital

    lead OTHER_GOV

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-08-15
Primary Completion
2020-10-30
Completion
2020-11-01

Countries

  • Kuwait

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04637633 on ClinicalTrials.gov